A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
Public ClinicalTrials.gov record NCT04687072. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and the Safety of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
Study identification
- NCT ID
- NCT04687072
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- argenx
- Industry
- Enrollment
- 207 participants
Conditions and interventions
Conditions
Interventions
- Efgartigimod PH20 SC Biological
- Placebo PH20 SC Other
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 15, 2020
- Primary completion
- Oct 8, 2023
- Completion
- Oct 8, 2023
- Last update posted
- Oct 30, 2024
2020 – 2023
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigator Site 0010116 | Springdale | Arkansas | 72758 | — |
| Investigator site 0010036 | Los Angeles | California | 90033 | — |
| Investigator Site 0010045 | Washington D.C. | District of Columbia | 20007 | — |
| Investigator Site 0010104 | Weston | Florida | 33331 | — |
| Investigator site 0010112 | Chicago | Illinois | 60612 | — |
| Investigator site 0010193 | Chicago | Illinois | 60637 | — |
| Investigator Site 0010079 | Lisle | Illinois | 60187 | — |
| Investigator Site 0010062 | Fort Wayne | Indiana | 46804 | — |
| Investigator site 0010042 | Iowa City | Iowa | 52242 | — |
| Investigator Site 0010083 | Detroit | Michigan | 48202 | — |
| Investigator Site 0010102 | Minneapolis | Minnesota | 55455 | — |
| Investigator site 0010040 | Columbus | Ohio | 43210 | — |
| Investigator Site 0010095 | Oklahoma City | Oklahoma | 73142 | — |
| Investigator Site 0010115 | Pittsburgh | Pennsylvania | 15222 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 186 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04687072, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 30, 2024 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04687072 live on ClinicalTrials.gov.